ArticleCancer gene therapy2005
Complex mosaicism is a novel approach to infectivity enhancement of adenovirus type 5-based vectors.
Article in Cancer gene therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 44 citations in OpenAlex.
- Superior infectivity of the fiber chimeric oncolytic adenoviruses Ad5/35 and Ad5/3 over Ad5-delta-24-RGD in primary glioma cultures.Molecular therapy oncolytics · 2022Article
- A new insight into aggregation of oncolytic adenovirus Ad5-delta-24-RGD during CsCl gradient ultracentrifugation.Scientific reports · 2021Article
- Review
- Efficient gene transfer into T lymphocytes by fiber-modified human adenovirus 5.BMC biotechnology · 2019Article
- Enhanced Delivery of Oncolytic Adenovirus by Neural Stem Cells for Treatment of Metastatic Ovarian Cancer.Molecular therapy oncolytics · 2019Article
- RGD-modifided oncolytic adenovirus exhibited potent cytotoxic effect on CAR-negative bladder cancer-initiating cells.Cell death & disease · 2015Article
- Enhancement of adenovirus delivery after ultrasound-stimulated therapy in a cancer model.Ultrasound in medicine & biology · 2013Article
- Systemic delivery of a breast cancer-detecting adenovirus using targeted microbubbles.Cancer gene therapy · 2012Article
- Chapter two--Adenovirus strategies for tissue-specific targeting.Advances in cancer research · 2012Review
- A genetic strategy for combined screening and localized imaging of breast cancer.Molecular imaging and biology · 2011Article
- Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Article
- Article
- Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor.Gene therapy · 2010Article
- Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review).Experimental and therapeutic medicine · 2010Article
- Chimeric adenoviral vectors incorporating a fiber of human adenovirus 3 efficiently mediate gene transfer into prostate cancer cells.The Prostate · 2010Article
- Development of fiber-substituted adenovirus vectors containing foreign peptides in the adenovirus serotype 35 fiber knob.Gene therapy · 2009Article
- Usage of integrin and heparan sulfate as receptors for mouse adenovirus type 1.Journal of virology · 2009Article
- Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo.Gene therapy · 2009Article
- Recent developments in the use of adenoviruses and immunotoxins in cancer gene therapy.Cancer gene therapy · 2007Review
- Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain.Journal of virology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of adenovirus type 5 (Ad5) for cancer therapy is limited by deficiency of its primary cell attachment receptor, coxsackie and adenovirus receptor (CAR), on cancer cells. Ad5 retargeting to alternate receptors through fiber genetic modification can be used to circumvent CAR dependence of its tropism, and thereby achieve infectivity enhancement. Here we propose and test a novel "complex mosaicism" approach for fiber modification, which combines serotype chimerism with peptide ligand(s) incorporation in a single-fiber molecule. We incorporated integrin-binding peptide RGD-4C in the HI-loop, at the carboxy (C)-terminus, or both locales of the Ad3 knob, in the context of Ad5/3 chimera fiber in order to retarget simultaneously the Ad vector to integrins and Ad3 receptors. The infectivity enhancement of the fiber modifications was assessed in various cancer cell lines as cancer-targeting models. Replication-defective complex mosaic Ad-luc vectors bearing chimeric fiber (F.5/3), with or without C-terminal RGD-modification of Ad3 knob, demonstrated up to 55-fold gene transfer increase in bladder cancer cell lines. Although this augmentation was primarily due to Ad3 receptor targeting, some contribution of RGD-mediated integrin-targeting was also observed, suggesting that complex mosaic modification can function in a dual-receptor targeting via a single Ad3 fiber knob.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.